Tactile Systems Stock Price, News & Analysis

Tactile Systems Technology, Inc. (Nasdaq: TCMD) announced its participation in a fireside chat at the ICR Conference 2021, scheduled for January 14th at 8:30 a.m. Eastern Time. The event will be held virtually from January 11th-14th. A live audio webcast will be available on the Company's investor relations website, with an archive accessible for replay after the event. Tactile Medical specializes in at-home therapy devices for chronic conditions like lymphedema, aiming to improve patients' quality of life while managing healthcare costs.

Tactile Systems Technology (TCMD) has announced its participation in several upcoming investor conferences. Management will engage in virtual 1x1 meetings at the Oppenheimer Fall MedTech Summit on November 12 and at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19. Additionally, a fireside chat will take place during the 32nd Annual Piper Sandler Healthcare Conference from December 1 to 3, accessible via the company’s investor relations website. This participation underscores TCMD's commitment to advancing at-home therapies for chronic conditions.

Tactile Systems Technology (TCMD) reported a 1% decrease in Q3 2020 revenue to $49.1 million compared to $49.6 million in Q3 2019, with COVID-19 impacting results. Operating income fell 44% to $1.8 million, while adjusted EBITDA was $6.0 million, down from $6.4 million year-over-year. The company experienced a net loss of $12.7 million for the nine months ending September 30, 2020. Updated revenue guidance suggests a full-year decline of 1% to 2% year-over-year, with expectations for modest growth in Q4.

Tactile Systems Technology, Inc. (TCMD) will release its third-quarter fiscal 2020 financial results after market close on November 2. A conference call will be held at 5:00 PM ET on the same day for a detailed discussion of the results, accessible via phone and live webcast. Tactile Medical specializes in at-home treatment devices for chronic diseases like lymphedema and chronic venous insufficiency, aiming to enhance patient quality of life while reducing overall healthcare costs.

Tactile Systems Technology (Nasdaq: TCMD) has announced its participation in the Canaccord Genuity 40th Annual Global Growth Conference on August 12th at 2:00 p.m. Eastern Time. The conference will be held virtually, and management will engage in a fireside chat. Interested parties can access a live audio webcast through the company’s investor relations website, with an archive available for later replay. Tactile Medical focuses on at-home therapies for chronic diseases, notably with their pneumatic compression devices for conditions like lymphedema.

Tactile Systems Technology, Inc. (Nasdaq: TCMD) reported a 22% decrease in second quarter revenue, totaling $35.1 million, down from $45.2 million in 2019, largely due to COVID-19 pandemic impacts. The operating loss surged to $8.0 million, contrasting with a $3.0 million profit in 2019. The company incurred a net loss of $13.9 million, or $(0.72) per diluted share. Despite challenges, management noted improvements in June compared to earlier months, and remains optimistic about recovery and growth in the $5 billion U.S. lymphedema market.

Tactile Medical (Nasdaq:TCMD) will release its second quarter fiscal 2020 financial results on August 3, after market close. The company's management will host a conference call at 5:00 p.m. ET to discuss the results, which can be accessed by dialing 877-407-3088 (international: 201-389-0927) with access code 13705943. A live webcast will also be available on Tactile Medical's investor relations website. The company specializes in developing devices for at-home treatment of chronic diseases, notably lymphedema and chronic venous insufficiency, aiming to improve patient care and reduce healthcare costs.

Tactile Systems Technology, Inc. (Nasdaq: TCMD) announced the appointment of Daniel L. Reuvers as President and CEO, effective June 8, 2020, succeeding Gerald R. Mattys, who is retiring after 15 years of service. Reuvers, with over 30 years in the medical device industry, is expected to lead the company’s next growth phase. His previous role at Integra LifeSciences involved significant business leadership. Mattys will provide consulting until June 2021 for a smooth transition. The company focuses on at-home treatments for chronic diseases like lymphedema.